Neo-adjuvant treatment of rectal cancer with capecitabine and oxaliplatin in combination with radiotherapy: a phase II study

Carlomagno, Chiara; Farella, A.; Bucci, Luigi; D’Armiento, Francesco Paolo; Pesce, Giuseppe; Pepe, Stefano; Cannella, Lucia; Pacelli, Roberto; Stefano, Alfonso De; Solla, Raffaele; D’Armiento, Maria; Placido, Sabino De

doi:10.1093/annonc/mdn719

Cited by 58 publications

(24 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Following preoperative CRT, TRG scores may reflect the characteristics of proliferation and resistance to hypoxia of residual cancer cells [35] [37]. TRG was reported to have prognostic value in LARC patients after preoperative CRT, and has also been previously reported as an independent prognostic factor for local recurrence [5,38,39].…”

Section: Discussionmentioning

confidence: 95%

Relationships Between SMAD3 Expression and Preoperative Fluoropyrimidine‐Based Chemoradiotherapy Response in Locally Advanced Rectal Cancer Patients

et al. 2015

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 95%

Relationships Between SMAD3 Expression and Preoperative Fluoropyrimidine‐Based Chemoradiotherapy Response in Locally Advanced Rectal Cancer Patients

et al. 2015

View full text Add to dashboard Cite

show abstract

“…This analysis involved patients enrolled in a phase II trial, whose entry criteria and main results have been reported elsewhere [25]. Briefly, 46 patients with a histologic diagnosis of rectal adenocarcinoma invading the intestinal wall or with pelvic lymph node involvement were treated preoperatively with 2 cycles of capecitabine and oxaliplatin combined with pelvic conformal radiotherapy (45 Gy in 5 weeks).…”

Section: Methodsmentioning

confidence: 99%

Predictive Factors of Complete Response to Neoadjuvant Chemoradiotherapy in Patients with Rectal Cancer

et al. 2010

View full text Add to dashboard Cite

Purpose: Pathological complete response (pCR) after neoadjuvant chemoradiotherapy is a favorable prognosticator in rectal cancer patients. We investigated whether the biological features of the primary tumor affect pCR. Materials and Methods:Forty-six patients treated with capecitabine-oxaliplatin and pelvic conformal radiotherapy were considered. Forty-three patients underwent surgery, and the pathologic response was scored according to the tumor regression grade (TRG) scale. Epidermal growth factor receptor (EGFR), vascular endothelial growth factor, poly(adenosine diphosphate-ribose) polymerase-1, X-ray cross-complimenting, thymidylate synthase (TS) and Ki67 expression were evaluated by immunohistochemistry on rectal biopsies obtained before chemoradiotherapy, and scored as the percentage of positive cells. Cutoffs were selected based on ROC analysis. The correlation between the biological factors and the TRG coded as TRG1 (pCR) versus TRG ≧2 (no pCR) was assessed by the χ² test and logistic regression analysis. Results: Low EGFR (p = 0.007), high TS (p = 0.002), and high Ki67 (p = 0.05) were strongly associated with pCR. Upon univariate analysis, TRG significantly affected disease-free survival (p = 0.03). Conclusions: pCR was significantly associated with high TS, high Ki67 and low EGFR expression. Patients with pCR have a significantly lower incidence of relapse.

show abstract

“…21 The addition of a second chemotherapeutic agent to neoadjuvant capecitabine-based CRT with cetuximab has not demonstrated a marked improvement to the rates of pCR or tumor downstaging in LARC, 24 which remain similar to those reported from studies of neoadjuvant capecitabine-based CRT, 12,13,25 or capecitabine-based CRT with irinotecan or oxaliplatin. 26,27 In the present study an assessment of radiological tumor response according to RECIST criteria was made. An overall response rate of 71% was recorded, which was similar to the that reported for patients with locally advanced SCCHN receiving cetuximab in combination with radiotherapy.…”

Section: Neoadjuvant Cetuximab Plus Crt On Tumor Response In Larcmentioning

confidence: 99%

A phase II study of cetuximab, capecitabine and radiotherapy in neoadjuvant treatment of patients with locally advanced resectable rectal cancer

Velenik

Ocvirk

Oblak

et al. 2010

European Journal of Surgical Oncology (EJSO)

View full text Add to dashboard Cite

Please cite this article as: Velenik V, Ocvirk J, Oblak I, Anderluh F. A phase II study of cetuximab, capecitabine and radiotherapy in neoadjuvant treatment of patients with locally advanced resectable rectal cancer, European Journal of Surgical Oncology (2009Oncology ( ), doi: 10.1016Oncology ( /j.ejso.2009 This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain. M A N U S C R I P T A C C E P T E D ARTICLE IN PRESS

show abstract

Neo-adjuvant treatment of rectal cancer with capecitabine and oxaliplatin in combination with radiotherapy: a phase II study

Abstract: CAP-OX-RT as preoperative treatment for rectal cancer induces a remarkable rate of complete or near-complete pathologically documented response and is well tolerated.

Cited by 58 publications

References 35 publications

Relationships Between SMAD3 Expression and Preoperative Fluoropyrimidine‐Based Chemoradiotherapy Response in Locally Advanced Rectal Cancer Patients

Relationships Between SMAD3 Expression and Preoperative Fluoropyrimidine‐Based Chemoradiotherapy Response in Locally Advanced Rectal Cancer Patients

Predictive Factors of Complete Response to Neoadjuvant Chemoradiotherapy in Patients with Rectal Cancer

A phase II study of cetuximab, capecitabine and radiotherapy in neoadjuvant treatment of patients with locally advanced resectable rectal cancer

Contact Info

Product

Resources

About